Breast Cancer-Targets and Therapy

Scope & Guideline

Exploring groundbreaking strategies in oncology.

Introduction

Explore the comprehensive scope of Breast Cancer-Targets and Therapy through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Breast Cancer-Targets and Therapy in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1179-1314
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessYes
CountryNew Zealand
TypeJournal
Convergefrom 2010 to 2024
AbbreviationBREAST CANCER-TARGET / Breast Cancer-Targets Ther.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal "Breast Cancer-Targets and Therapy" aims to provide a platform for high-quality research focused on breast cancer treatments, diagnostics, and the underlying biological mechanisms of the disease. The journal emphasizes the integration of clinical and laboratory research to improve patient outcomes through innovative therapeutic strategies.
  1. Targeted Therapies and Drug Development:
    The journal publishes articles on the development and application of targeted therapies, including antibody-drug conjugates, immunotherapies, and small molecule inhibitors, aimed at specific breast cancer subtypes such as HER2-positive and triple-negative breast cancer.
  2. Biomarkers and Prognostic Indicators:
    Research focusing on identifying and validating biomarkers for breast cancer diagnosis, prognosis, and treatment response is a core area. This includes studies on circulating tumor DNA, microRNAs, and other molecular markers that can aid in personalized treatment approaches.
  3. Radiotherapy Innovations:
    The journal highlights advances in radiotherapy techniques, including hypofractionation and the use of novel dosimetric approaches to reduce toxicity and improve outcomes for breast cancer patients.
  4. Clinical Guidelines and Practice:
    Articles that discuss clinical guidelines, treatment protocols, and real-world evidence in the management of breast cancer are frequently featured, aiming to bridge the gap between research findings and clinical practice.
  5. Epidemiological Studies and Risk Factors:
    The journal also covers epidemiological research that identifies risk factors, lifestyle influences, and socio-economic determinants associated with breast cancer incidence and outcomes.
  6. Patient-Centric Research:
    There is a commitment to exploring patient perspectives, quality of life, and psychosocial aspects of breast cancer treatment, ensuring that research translates to tangible benefits for patients.
Recent publications in "Breast Cancer-Targets and Therapy" indicate several emerging themes that reflect the latest advancements and shifts in breast cancer research. These trends highlight the journal's responsiveness to new scientific insights and clinical needs.
  1. Liquid Biopsies and Non-Invasive Diagnostics:
    The emergence of research on liquid biopsies, particularly the use of plasma exosomes and circulating tumor DNA, signifies a growing interest in non-invasive diagnostics that can monitor disease progression and treatment response.
  2. Immunotherapy Advances:
    There is a notable increase in studies exploring immunotherapy, including novel checkpoint inhibitors and vaccine strategies, which are becoming central to the treatment landscape for various breast cancer subtypes.
  3. Precision Medicine:
    Research focusing on precision medicine approaches, including genetic profiling and individualized treatment plans based on tumor characteristics, is gaining traction, reflecting a shift towards tailored therapies.
  4. Nanotechnology in Treatment Delivery:
    The application of nanotechnology for drug delivery systems and targeted therapies is an emerging theme, showcasing innovative methods to enhance the efficacy and reduce side effects of breast cancer treatments.
  5. Role of the Tumor Microenvironment:
    There is an increasing emphasis on understanding the tumor microenvironment and its role in breast cancer progression and therapy resistance, which is critical for developing effective treatment strategies.

Declining or Waning

As the field of breast cancer research evolves, certain themes appear to be experiencing a decline in focus within the journal. This shift may reflect changing research priorities or advancements in treatment modalities.
  1. Traditional Chemotherapy Approaches:
    There seems to be a waning emphasis on traditional chemotherapy regimens in favor of targeted and immunotherapeutic strategies, reflecting a broader trend towards personalized medicine.
  2. Use of Traditional Chinese Medicine:
    While previously a niche area of interest, the volume of research related to traditional Chinese medicine in breast cancer treatment appears to be decreasing, as more focus shifts towards evidence-based pharmacological therapies.
  3. Basic Science Studies:
    There has been a noticeable reduction in purely basic science studies that do not directly translate to clinical applications, as the journal increasingly favors translational research that impacts patient care.

Similar Journals

Breast Cancer-Basic and Clinical Research

Advancing knowledge, transforming treatment.
Publisher: SAGE PUBLICATIONS LTDISSN: 1178-2234Frequency: 1 issue/year

Breast Cancer-Basic and Clinical Research is a premier open access journal published by SAGE Publications Ltd, dedicated to advancing the understanding and treatment of breast cancer through a comprehensive approach that integrates basic and clinical research findings. Since its inception in 2008, this journal has aimed to serve as a vital platform for researchers, healthcare professionals, and students in the fields of oncology and cancer research, providing them with timely access to significant new research, clinical trials, and innovative methodologies. With its current rankings placing it in the Q3 quartile for Cancer Research and Oncology, it reflects a steady commitment to quality and relevance, ranking #167/404 in Medicine - Oncology and #133/230 in Biochemistry, Genetics and Molecular Biology - Cancer Research as of 2023. The journal is designed to foster dialogue and collaboration across disciplines, enabling advancements in therapeutic strategies and patient care. Researchers and professionals will find it an invaluable resource as it continues to push the frontiers of knowledge in breast cancer research.

MEDICAL ONCOLOGY

Elevating the standards of oncology with peer-reviewed excellence.
Publisher: HUMANA PRESS INCISSN: 1357-0560Frequency: 1 issue/year

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.

Turk Onkoloji Dergisi-Turkish Journal of Oncology

Fostering impactful discoveries in the realm of oncology.
Publisher: KARE PUBLISSN: 1300-7467Frequency: 4 issues/year

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

ONCOLOGY

Connecting researchers and clinicians in the fight against cancer.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Cancer Research Communications

Innovating cancer treatment through shared insights.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Nature Reviews Clinical Oncology

Shaping the Future of Oncology with Evidence
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

INTERNATIONAL JOURNAL OF ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Breast Cancer Management

Innovative Insights for Effective Management.
Publisher: FUTURE MEDICINE LTDISSN: 1758-1923Frequency: 4 issues/year

Breast Cancer Management is a pivotal journal in the field of oncology and radiology, published by FUTURE MEDICINE LTD. Since its transition to Open Access in 2018, the journal has aimed to democratize access to cutting-edge research focused on innovative treatments and management strategies for breast cancer. With an ISSN of 1758-1923 and an E-ISSN of 1758-1931, it provides a platform for researchers and clinicians to share findings that enhance patient care and outcomes. The journal has garnered significant attention, placing in the Q3 quartile in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023. Positioned in the United Kingdom, its editorial focus and rigorous peer-review process ensure that it remains at the forefront of breast cancer research. As breast cancer continues to be a major health concern globally, Breast Cancer Management serves as an essential resource for advancing knowledge and fostering collaboration among professionals in this vital area of medicine.

JCO Precision Oncology

Empowering Cancer Research with Tailored Therapies
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 1 issue/year

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Oncologie

Transforming cancer treatment through rigorous research.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.